What is AMLX's current stock price?

AMLX (Amylyx Pharmaceuticals, Inc.) is currently trading at $13.53 with a market cap of $1.12B.

What sector is Amylyx Pharmaceuticals, Inc. in?

Amylyx Pharmaceuticals, Inc. (AMLX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is AMLX a good stock to buy?

Analysts have a Buy consensus on AMLX with a price target of $24.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

AMLX Amylyx Pharmaceuticals, Inc.

Healthcare

$13.53+0.00%OpenMarket Cap: $1.12B

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

5.50

P/S

0.00

EV/EBITDA

-6.02

DCF Value

$2.30

FCF Yield

-10.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-55.7%

ROA

-51.1%

ROIC

-57.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-41.3M	$—
Q4 null	$0.00	$-33.0M	$—
FY null	$0.00	$-144.7M	$—
Q3 null	$0.00	$-34.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$24.50

Target (Median)

$24.50

Target Range

$21.00 - $28.00

0 Strong Buy11 Buy1 Hold0 Sell0 Strong Sell

MizuhoOutperform

2026-04-28

HC Wainwright & Co.Buy

2026-03-25

GuggenheimBuy

2026-03-19

B of A SecuritiesBuy

2026-02-20

HC Wainwright & Co.Buy

2026-02-10

Trading Activity

Insider Trades

View All

Mazzariello Ginaofficer: Chief Legal Officer

SellMon Mar 09

Mazzariello Ginaofficer: Chief Legal Officer

SellMon Mar 09

Klee Justin B.director, officer: Co-Chief Executive Officer

SellMon Mar 09

Klee Justin B.director, officer: Co-Chief Executive Officer

SellMon Mar 09

FRATES JAMES Mofficer: Chief Financial Officer

SellMon Mar 09

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.10

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Peers